PALOMA-3 中哌柏西利联合氟维司群长期获益的预测因素
PALOMA-3 研究探索内分泌抵抗 HR+/HER2- 转移性乳腺癌患者中,哌柏西利联合氟维司群长期获益(治疗≥18个月)的预测因素。截至2016年8月,哌柏西利组100例(29%)、安慰剂组26例(15%)达到长期获益,两组长期获益者共享基线肿瘤负荷较低、既往治疗较少等特征,但未发现特异性分子或临床预测因子。
要点
- 哌柏西利联合氟维司群组长期获益比例高于安慰剂联合氟维司群组(29% vs 15%)。
- 长期获益者基线肿瘤负荷较低、既往治疗线数较少,且 ESR1/PIK3CA 突变率较低。
- 未发现可特异性预测哌柏西利联合氟维司群长期获益的分子或临床因素。
核心结论
- 部分内分泌抵抗的 HR+/HER2- 转移性乳腺癌患者可从哌柏西利联合氟维司群获得显著且持久的获益,而安慰剂联合氟维司群获得类似疗效的患者较少。
- 探索性分析未识别出可预测哌柏西利联合氟维司群长期获益的特异性分子或临床因素。
研究设计与样本
- PALOMA-3 为随机 2:1 对照研究,纳入内分泌抵抗的 HR+/HER2- 转移性乳腺癌患者(绝经前/围绝经期/绝经后)。
- 患者接受氟维司群 500 mg 联合哌柏西利 125 mg/d(3/1 方案,n=347)或安慰剂(n=174)。
- 比较长期获益(治疗持续时间≥18个月)与未长期获益患者的基线特征、突变状态和激素受体表达水平。
主要发现
- 截至2016年8月,哌柏西利联合氟维司群组100例(29%)和安慰剂联合氟维司群组26例(15%)达到长期获益。
- 长期获益者通常基线疾病负荷较低:哌柏西利组单部位病灶40% vs 29%,单纯骨病灶32% vs 22%;安慰剂组单部位病灶69% vs 29%,单纯骨病灶46% vs 17%。
- 长期获益者既往治疗较少:哌柏西利组≤2线既往治疗者69% vs 56%,安慰剂组73% vs 60%。
- 两组长期获益者的基线 ESR1 和 PIK3CA 突变率均较低;雌激素受体 H 评分中位数相似,但孕激素受体 H 评分较高。
临床怎么用
- 对于内分泌抵抗的 HR+/HER2- 转移性乳腺癌,哌柏西利联合氟维司群可使部分患者获得持久获益。
- 基线肿瘤负荷较低、既往治疗线数较少的患者可能更易获得长期获益,但尚无特异性预测因子指导个体化选择。
局限性
- 本文为探索性分析,未识别出可预测哌柏西利联合氟维司群长期获益的特异性分子或临床因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive of long-term benefit. METHODS: Premenopausal-peri/postmenopausal patients with endocrine-resistant, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative MBC were randomised 2:1 to fulvestrant (500 mg) and either palbociclib (125 mg/d; 3/1 schedule; n = 347) or placebo (n = 174). Baseline characteristics, mutation status and HR expression levels were compared in patients with and without prolonged benefit (treatment duration ≥18 months). RESULTS: By August 2016, 100 patients (29%) on palbociclib-fulvestrant and 26 (15%) on placebo-fulvestrant demonstrated prolonged benefit, with long-term responders in both arms sharing common clinical characteristics. They usually had less disease burden at baseline versus those treated <18 months, such as having one disease site (40% vs 29% on palbociclib-fulvestrant and 69% vs 29% on placebo-fulvestrant), bone-only disease (32% vs 22% and 46% vs 17%) and were less heavily pretreated (69% vs 56% and 73% vs 60% had ≤2 prior therapies). Baseline tumour ESR1 and PIK3CA mutation rates were lower among long-term responders in both arms; median oestrogen receptor H-scores were similar, whereas progesterone receptor H-scores were higher among long-term responders. CONCLUSIONS: This exploratory analysis demonstrates that some patients with endocrine-resistant MBC derive significant and prolonged benefit when treated with palbociclib-fulvestrant, with fewer patients experiencing similar efficacy with placebo-fulvestrant. The current analysis did not identify specific molecular or clinical factors prognostic of long-term benefit with palbociclib-fulvestrant (ClinicalTrials.gov, NCT01942135).
引用
- Cristofanilli M, DeMichele A, Giorgetti C, et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur J Cancer. 2018. PMID: 30308388. doi:10.1016/j.ejca.2018.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。